Cellectar’s 140M Dollar Lifeline Sends Shares Soaring Over 130%

Cellectar Biosciences (NASDAQ: CLRB) shares are surging more than 130% after the company lined up up to 140 million dollars in new financing.

The funding was oversubscribed, signaling strong demand from investors and providing a major cash boost for this clinical‑stage oncology company.

How the 140M dollar financing works

Cellectar structured the deal as an up to 140 million dollar financing package, which includes an initial funding tranche and follow‑on capital tied to future milestones and share‑price performance.

Part of the structure allows additional proceeds if the stock trades at or above 130% of the exercise price for a set number of trading days, effectively rewarding both the company and investors if momentum continues.

Why this matters for the pipeline

The company plans to use the funds to support a confirmatory study and a New Drug Application (NDA) filing for accelerated approval of its lead candidate, iopofosine I‑131, in Waldenström’s macroglobulinemia, a rare blood cancer.

This drug has already shown activity in earlier studies, and the new capital is intended to carry the program through key late‑stage milestones and regulatory work, which are often the most expensive steps for a small biotech.

What Cellectar does

Cellectar is a clinical biopharmaceutical company focused on phospholipid drug conjugates designed to deliver targeted radiation or chemotherapy directly to cancer cells.

Its lead asset, iopofosine I‑131 (also known as CLR 131), is being studied across several B‑cell malignancies, including Waldenström’s macroglobulinemia, multiple myeloma, and non‑Hodgkin’s lymphoma, as well as in early‑stage trials for certain solid tumors and pediatric cancers.

What investors may want to watch next

The financing significantly extends Cellectar’s cash runway, reducing near‑term funding risk while it pursues pivotal data and an NDA filing, which are potential value‑defining catalysts.

However, the structure likely involves dilution and warrant or option components, so investors should review the full terms to understand how ownership and upside may be shared as the stock and the science progress.